Dr. Meng-Yin YANGTaiwan
Taichung Veterans General Hospital
Current Position
to present Director of Neurosurgical Oncology, Neurology Medical Center, Taichung Veterans General Hospital
to present Deputy Director of Cell Therapy and Regenerative Medicine Center, Taichung Veterans General Hospital
to present Vice Secretary-General and Chairperson of the International Medical Committee of the Taiwan Neurosurgical Society. Secretary-General of the Taiwan Neurosurgical Spine Society
Academic Experiences
- National Defense Medical Center, Taipei, Taiwan, M.D. degree
- Clinical and research fellow, Department of Surgery/Neurosurgery, David Geffen School of Medicine at UCLA, LA, United States
- Doctor of Philosophy, Graduate Institute of Medical Science, National Defense Medical Center, Taipei, Taiwan
Specialty & Expertise
Neurosurgery (brain surgery, spine surgery, immunotherapy for brain tumor, cell therapy)
Presentation Information
High expression of L-VEGF144 in glioblastoma multiforme and its impact on bevacizumab treatment outcomes
1108 16:10-16:20
Neuro-oncology/305
Abstract Introduction Apreviousstudyconfirmedthatanovelsplicingvariantoflargevascularendothelialgrowthfactor(L-VEGF) termed L-VEGF144, a nucleolus protein, is found in glioblastoma cells and specimens, but the actual biological function and clinical significance of L-VEGF144 remain unclear. Methods In this study, we analyzed the expression of L-VEGF144 in 68 glioblastoma multiforme specimens using reverse transcriptase-polymerase chain reaction analysis. Results The results showed that the high expression of L-VEGF144 was associated with a poor prognosis in the bevaci- zumab plus concurrent chemoradiotherapy with temozolomide treatment. In addition, we constructed a series truncated and mutant form of L-VEGF144 to confirm that exon 6a of L-VEGF144 is able to engage in the nuclear importation and found that 8 lysines within exon 6a play a critical role in the nucleolus aggregation of L-VEGF144. Also, the transfection of the L-VEGF144 increased the number of nucleoli. Furthermore, the recombinant protein Flag-L-VEGF144 and commercial VEGF protein have similar growth stimulatory activities in terms of inducing glioblastoma cell proliferation in vitro. Conclusions Taken together, these results indicated that the expression of L-VEGF144 could potentially serve as an inde- pendent indicator of poor prognosis in bevacizumab treatment. Keywords Bevacizumab · Nucleolus protein · Novel VEGF isoform · GBM Prognosis · Mitogen